BioMérieux Stock Drops 2.75% and Nears Key Support at 92.20 Euros

Deutsche Bank Lowers Price Target

In a note published on March 3, Deutsche Bank revised its price target on bioMérieux downwards from 131 to 126 euros, while maintaining its buy recommendation. At the current price of 95.40 euros, this target implies a potential revaluation of about 32%, indicating a significant gap between market valuation and the German research firm's appraisal. This adjustment comes as the Lyon-based group prepares to publish its first quarter 2026 revenue on April 23, an event that will be the next fundamental catalyst for the stock. The semi-annual results are expected on July 28. Until then, the market will assess bioMérieux's ability to maintain its commercial momentum in an uncertain macroeconomic environment.

Technical Analysis Indicates Pressure

Technically, the stock is now very close to its support threshold at 92.20 euros, after having significantly dropped below its 50-day moving average (102.13 euros) and even more so below its 200-session moving average (112.41 euros). This dual downward crossing indicates a lasting deterioration of the trend, with the stock currently about 15% below the 200-day moving average. Concurrently, the Relative Strength Index (RSI) stands at 70, a level that borders the so-called overbought zone. This indicator, which measures the speed and magnitude of recent price changes, can signal a temporary exhaustion of a directional movement. In this case, its reading contrasts with the medium-term bearish trend, which could reflect a recent technical rebound that has not been sufficient to reverse the overall trajectory. The nearest resistance is at 104.60 euros, a level the stock would need to reclaim to consider a significant turnaround. In the short term, the proximity of the support at 92.20 euros will be a critical benchmark: breaking it could lead to further weakness.